Relief Therapeutics Holding SA (SWX:RLF)
3.300
-0.050 (-1.49%)
Sep 30, 2025, 4:20 PM CET
SWX:RLF Revenue
Relief Therapeutics Holding had revenue of 1.22M CHF in the half year ending June 30, 2025, a decrease of -57.10%. This brings the company's revenue in the last twelve months to 4.05M, down -52.81% year-over-year. In the year 2024, Relief Therapeutics Holding had annual revenue of 8.42M with 39.52% growth.
Revenue (ttm)
4.05M
Revenue Growth
-52.81%
P/S Ratio
10.46
Revenue / Employee
144.79K
Employees
31
Market Cap
42.41M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 8.42M | 2.38M | 39.52% |
Dec 31, 2023 | 6.03M | -48.00K | -0.79% |
Dec 31, 2022 | 6.08M | 2.76M | 83.11% |
Dec 31, 2021 | 3.32M | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Roche Holding AG | 63.49B |
Novartis AG | 43.89B |
Lonza Group AG | 7.09B |
Galderma Group AG | 3.73B |
Alcon | 7.97B |
Sandoz Group AG | 8.42B |
Straumann Holding AG | 2.58B |
Sonova Holding AG | 3.87B |
Relief Therapeutics Holding News
- 6 weeks ago - Relief Therapeutics Publishes 2025 Half-Year Report - Accesswire
- 7 weeks ago - Relief Therapeutics Advances Publication of 2025 Half-Year Report - Accesswire
- 2 months ago - Relief Therapeutics reports proposed business combination with NeuroX - Seeking Alpha
- 2 months ago - Relief Therapeutics Announces Proposed Business Combination with NeuroX, Successor to MindMaze - Accesswire
- 3 months ago - Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011 - Accesswire
- 3 months ago - Relief Therapeutics Announces Results of Annual General Meeting - Accesswire
- 4 months ago - Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011 - Accesswire
- 4 months ago - Relief Therapeutics Publishes 2025 Annual General Meeting Agenda - Accesswire